Last reviewed: June 5, 2026
Last updated: June 5, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 receptor agonists have emerged as a breakthrough treatment for weight management, with clinical trial data showing that patients using semaglutide lose an average of 15% of their body weight over one year. PlexusDx provides access to compounded semaglutide and other GLP-1 medications from licensed 503A pharmacies, helping patients across all 50 states achieve personalized weight loss outcomes without insurance requirements.
Average Weight Loss Numbers from Clinical Trials
The STEP trials, which studied semaglutide for weight loss, documented that participants lost between 10% and 22% of their initial body weight depending on the dose used and duration of treatment. In the primary STEP 1 trial, patients receiving the highest dose of semaglutide lost approximately 15% of their body weight after 68 weeks, compared to a 2.6% loss in the placebo group. These results represent some of the most significant weight reduction achieved by any medication in clinical history.
Tirzepatide, a dual GLP-1 and GIP receptor agonist, demonstrated even greater weight loss in the SURMOUNT trials, with some patients losing up to 22% of their body weight over 72 weeks. The variation in results depends on multiple factors including starting weight, metabolism, adherence to medication, dietary changes, and physical activity levels. PlexusDx offers both semaglutide and tirzepatide formulations to help patients find the option best suited to their individual response profile.
How Individual Genetics Influence Your Weight Loss Potential
Your genetic makeup plays a critical role in how effectively GLP-1 medications work for weight loss. Key genetic variants—such as those in the GLP1R, GIPR, FTO, and MC4R genes—affect how your body responds to appetite-suppressing signals and regulates energy storage. PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights to identify which peptide-based approach may work best for your unique biology.
The FTO rs9939609 variant, for example, influences fat mass accumulation and hunger signaling, meaning individuals carrying certain alleles may experience different baseline appetite levels and weight loss trajectories on GLP-1 therapy. The GLP1R rs6923761 variant directly affects the sensitivity of your GLP-1 receptors, which determines how responsive your body will be to semaglutide or tirzepatide. Understanding these genetic predispositions helps PlexusDx specialists recommend whether a standard GLP-1, a dual compound, or a microdose protocol aligns with your metabolic profile.
Realistic Timelines for Seeing Weight Loss Results
Most patients using GLP-1 medications notice appetite reduction within the first 1–2 weeks of starting treatment, though measurable weight loss typically appears after 4–6 weeks of consistent use. Significant weight reduction—defined as 5–10% body weight loss—often becomes evident by 8–12 weeks. The full clinical benefit observed in trials accumulated over 16–20 weeks of continuous therapy, with some patients continuing to lose weight for the full duration of the studies.
Weight loss tends to plateau after 6–12 months for many patients, meaning your rate of loss may slow even as you continue taking medication. This plateau represents your new metabolic set point and is considered a successful outcome rather than treatment failure. Combining GLP-1 medication with consistent dietary changes, increased protein intake, and regular physical activity typically produces better long-term weight maintenance compared to medication alone.
Factors That Affect Your Personal Weight Loss Amount
Your starting body weight is one of the strongest predictors of total weight loss with GLP-1 therapy—patients with higher starting weights typically lose more pounds in absolute terms, though the percentage of body weight lost remains relatively consistent. Baseline metabolic health, including existing insulin resistance and blood sugar control, influences how quickly your body responds. Age, sex, medications you currently take, sleep quality, stress levels, and adherence to dosing schedules all contribute to individual variation in outcomes.
Dietary choices matter significantly because GLP-1 medications suppress appetite but do not prevent calorie consumption—eating high-calorie foods in smaller portions may limit weight loss compared to choosing nutrient-dense, lower-calorie options. Physical activity amplifies results; studies show that patients combining medication with regular exercise lose more weight and experience better cardiovascular improvements than those relying on medication alone. PlexusDx patients using the Precision Peptide Genetic Test receive personalized guidance on which dietary and activity approaches align with their genetic metabolic predispositions, optimizing their individual weight loss potential.
PlexusDx Semaglutide and Tirzepatide for Sustainable Weight Loss
PlexusDx compounded semaglutide injection starts at $149 per month and provides consistent GLP-1 receptor activation to reduce appetite and improve metabolic function. All PlexusDx medications are sourced from licensed 503A compounding pharmacies, ensuring quality and safety standards. Your dose may need to go up as your body adjusts, but your price remains flat—no surprise increases based on dose escalation.
For patients seeking stronger dual-pathway activation, PlexusDx offers compounded tirzepatide injection starting at $249 per month, which targets both GLP-1 and GIP receptors for potentially greater weight loss. PlexusDx serves all 50 states without requiring insurance, membership fees, or pre-authorization delays. Adding the Precision Peptide Genetic Test ($99 add-on after your first month) identifies your specific genetic pathway strengths, helping your PlexusDx specialist optimize your medication choice and dosing strategy for maximum results.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I lose 50 pounds or more with GLP-1 medications?
Yes, patients with higher starting weights frequently lose 50+ pounds over the course of 12–18 months of consistent GLP-1 therapy. Clinical trials documented weight losses ranging from 25 to 75+ pounds depending on individual factors, starting body weight, and lifestyle modifications.
How fast does weight loss happen with semaglutide?
Appetite suppression occurs within 1–2 weeks for many patients, but measurable weight loss typically appears after 4–6 weeks. In clinical trials, significant reductions (5–10% body weight) were observed by 8–12 weeks, with maximum results accumulating over 16–20 weeks of treatment.
Does everyone lose the same amount of weight on GLP-1?
No—weight loss varies significantly between individuals due to genetics, starting body weight, metabolism, dietary adherence, and physical activity. Two people on the same GLP-1 dose may experience different results.
Is weight loss with GLP-1 medications permanent?
Weight loss achieved during GLP-1 therapy can be maintained with continued medication use, consistent dietary habits, and regular physical activity. Studies show that discontinuing GLP-1 medications without lifestyle changes often results in weight regain, though some patients retain a portion of their loss.
Can genetic testing predict how much weight I'll lose?
PlexusDx Precision Peptide Genetic Test cannot predict exact weight loss amounts but identifies your genetic predispositions in 14 metabolic pathways and 150+ genetic insights related to appetite, energy storage, and peptide responsiveness.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Are All GLP-1 the Same? Exploring the Differences in GLP-1 Agonists
How Does Ozempic Help Heart Disease? A Path to Better Cardiovascular Health